NCT05481463

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

A Open-label, Single-arm, Single-center, Phase II Clinical Study of Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

Detailed description

surufatinib:250mg,QD,Q4W TAS-102:35mg/m2,D1-5,D8-12,Q4W

Conditions

• Pancreatic Neoplasms

Interventions

Type	Name	Description
DRUG	Surufatinib	surufatinib,250mg, qd, po, 28 days for a cycle
DRUG	TAS-102	TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle

Timeline

• Start date: 2023-01-30
• Primary completion: 2025-03-31
• Completion: 2025-05-10
• First posted: 2022-08-01
• Last updated: 2025-05-28

Locations

1 site across 1 country: China